NATCO files ANDA for Oseltamivir, (Tamiflu®) ties up with Alvogen, gets First to File Status
Feb 19th 2011
The Hyderabad based NATCO Pharma Limited is pleased to announce the acceptance of its Abbreviated New Drug Application for the generic version of Oseltamivir Phosphate capsules.
Oseltamivir Phosphate is used in the treatment of bird and swine-flu infections. Sold under the brand name Tamiflu®, the product clocked global annual sales in the region of US $ 1Billion.
NATCO has tied up with the Luxemburg based Alvogen IPCO S.a.r.l., for marketing and sales of Oseltamivir Phosphate in the USA.
NATCO is the "first applicant" to file an ANDA for the generic version of Tamiflu® and, should the ANDA be approved, may be entitled to 180 days of generic market exclusivity.